<?xml version='1.0' encoding='utf-8'?>
<document id="18367972"><sentence text="Pharmacokinetics of mycophenolate mofetil and sirolimus in children."><entity charOffset="20-41" id="DDI-PubMed.18367972.s1.e0" text="mycophenolate mofetil" /><entity charOffset="46-55" id="DDI-PubMed.18367972.s1.e1" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.18367972.s1.e0" e2="DDI-PubMed.18367972.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s1.e0" e2="DDI-PubMed.18367972.s1.e1" /></sentence><sentence text="This review summarizes the pharmacokinetics in children and youths of 2 commonly used immunosuppressive drugs, mycophenolate mofetil (MMF) and sirolimus (Sir), as presented at the IATDMCT 2007 conference"><entity charOffset="111-132" id="DDI-PubMed.18367972.s2.e0" text="mycophenolate mofetil" /><entity charOffset="134-137" id="DDI-PubMed.18367972.s2.e1" text="MMF" /><entity charOffset="143-152" id="DDI-PubMed.18367972.s2.e2" text="sirolimus" /><entity charOffset="154-157" id="DDI-PubMed.18367972.s2.e3" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s2.e0" e2="DDI-PubMed.18367972.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s2.e0" e2="DDI-PubMed.18367972.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18367972.s2.e0" e2="DDI-PubMed.18367972.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18367972.s2.e0" e2="DDI-PubMed.18367972.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18367972.s2.e1" e2="DDI-PubMed.18367972.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18367972.s2.e1" e2="DDI-PubMed.18367972.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18367972.s2.e1" e2="DDI-PubMed.18367972.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18367972.s2.e2" e2="DDI-PubMed.18367972.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18367972.s2.e2" e2="DDI-PubMed.18367972.s2.e3" /></sentence><sentence text=" The review focuses on the developmental changes of drug disposition during childhood and adolescence" /><sentence text=" Regarding mycophenolate mofetil, the authors were unable to demonstrate age dependency of MMF in combination with cyclosporine"><entity charOffset="11-32" id="DDI-PubMed.18367972.s4.e0" text="mycophenolate mofetil" /><entity charOffset="115-127" id="DDI-PubMed.18367972.s4.e1" text="cyclosporine" /><entity charOffset="91-102" id="DDI-PubMed.18367972.s4.e2" text="MMF" /><pair ddi="false" e1="DDI-PubMed.18367972.s4.e0" e2="DDI-PubMed.18367972.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s4.e0" e2="DDI-PubMed.18367972.s4.e2" /><pair ddi="false" e1="DDI-PubMed.18367972.s4.e0" e2="DDI-PubMed.18367972.s4.e1" /><pair ddi="false" e1="DDI-PubMed.18367972.s4.e2" e2="DDI-PubMed.18367972.s4.e2" /><pair ddi="false" e1="DDI-PubMed.18367972.s4.e2" e2="DDI-PubMed.18367972.s4.e1" /></sentence><sentence text=" By contrast, there was an inverse relationship between age and the dose-normalized mycophenolate (MPA) area-under-the-time-concentration curve (AUC) in children who received concomitant tacrolimus (Tac)"><entity charOffset="84-97" id="DDI-PubMed.18367972.s5.e0" text="mycophenolate" /><entity charOffset="99-102" id="DDI-PubMed.18367972.s5.e1" text="MPA" /><entity charOffset="187-197" id="DDI-PubMed.18367972.s5.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.18367972.s5.e0" e2="DDI-PubMed.18367972.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s5.e0" e2="DDI-PubMed.18367972.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18367972.s5.e0" e2="DDI-PubMed.18367972.s5.e2" /><pair ddi="false" e1="DDI-PubMed.18367972.s5.e1" e2="DDI-PubMed.18367972.s5.e1" /><pair ddi="false" e1="DDI-PubMed.18367972.s5.e1" e2="DDI-PubMed.18367972.s5.e2" /></sentence><sentence text=" Dose-normalized MPA AUCs were higher than commonly observed in adult patients"><entity charOffset="17-26" id="DDI-PubMed.18367972.s6.e0" text="MPA" /></sentence><sentence text=" It can be hypothesized that the age dependency is related to developmental changes in the expression of the UDP-glucuronosyltransferases" /><sentence text=" Sirolimus half-life and mean residence time (MRT) are shorter than in adults"><entity charOffset="1-3" id="DDI-PubMed.18367972.s8.e0" text="Sir" /></sentence><sentence text=" Similar to that in adults, there is a profound drug-drug interaction between cyclosporine and Sir"><entity charOffset="78-90" id="DDI-PubMed.18367972.s9.e0" text="cyclosporine" /><entity charOffset="95-106" id="DDI-PubMed.18367972.s9.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s9.e0" e2="DDI-PubMed.18367972.s9.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s9.e0" e2="DDI-PubMed.18367972.s9.e1" /></sentence><sentence text=" In our own experience, Sir was started at 0"><entity charOffset="24-26" id="DDI-PubMed.18367972.s10.e0" text="Sir" /></sentence><sentence text="13 +/- 0" /><sentence text="05 mg/kg/day" /><sentence text=" The average Sir AUC was 64"><entity charOffset="13-15" id="DDI-PubMed.18367972.s13.e0" text="Sir" /></sentence><sentence text="9 +/- 29" /><sentence text="7 ng*h/mL" /><sentence text=" The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7"><entity charOffset="60-74" id="DDI-PubMed.18367972.s16.e0" text="12-hydroxy-Sir" /><entity charOffset="71-84" id="DDI-PubMed.18367972.s16.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s16.e0" e2="DDI-PubMed.18367972.s16.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s16.e0" e2="DDI-PubMed.18367972.s16.e1" /></sentence><sentence text="6 (0" /><sentence text="2-18" /><sentence text="8); 46-hydroxy-Sir, 3"><entity charOffset="4-18" id="DDI-PubMed.18367972.s19.e0" text="46-hydroxy-Sir" /><entity charOffset="15-28" id="DDI-PubMed.18367972.s19.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s19.e0" e2="DDI-PubMed.18367972.s19.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s19.e0" e2="DDI-PubMed.18367972.s19.e1" /></sentence><sentence text="1 (0" /><sentence text="0-12" /><sentence text="4); 24-hydroxy-Sir, 4"><entity charOffset="4-18" id="DDI-PubMed.18367972.s22.e0" text="24-hydroxy-Sir" /><entity charOffset="15-28" id="DDI-PubMed.18367972.s22.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s22.e0" e2="DDI-PubMed.18367972.s22.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s22.e0" e2="DDI-PubMed.18367972.s22.e1" /></sentence><sentence text="3 (0" /><sentence text="0-12" /><sentence text="6); piperidine-hydroxy-Sir, 3"><entity charOffset="4-26" id="DDI-PubMed.18367972.s25.e0" text="piperidine-hydroxy-Sir" /><entity charOffset="23-44" id="DDI-PubMed.18367972.s25.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s25.e0" e2="DDI-PubMed.18367972.s25.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s25.e0" e2="DDI-PubMed.18367972.s25.e1" /></sentence><sentence text="5 (0" /><sentence text="0-8" /><sentence text="3); 39-desmethyl-Sir, 3"><entity charOffset="4-20" id="DDI-PubMed.18367972.s28.e0" text="39-desmethyl-Sir" /><entity charOffset="17-32" id="DDI-PubMed.18367972.s28.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s28.e0" e2="DDI-PubMed.18367972.s28.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s28.e0" e2="DDI-PubMed.18367972.s28.e1" /></sentence><sentence text="6 (0" /><sentence text="0-11" /><sentence text="3); 16-desmethyl-Sir, 5"><entity charOffset="4-20" id="DDI-PubMed.18367972.s31.e0" text="16-desmethyl-Sir" /><entity charOffset="17-32" id="DDI-PubMed.18367972.s31.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s31.e0" e2="DDI-PubMed.18367972.s31.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s31.e0" e2="DDI-PubMed.18367972.s31.e1" /></sentence><sentence text="0 (0" /><sentence text="1-9" /><sentence text="9); and di-hydroxy-Sir, 4"><entity charOffset="8-22" id="DDI-PubMed.18367972.s34.e0" text="di-hydroxy-Sir" /><entity charOffset="19-32" id="DDI-PubMed.18367972.s34.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s34.e0" e2="DDI-PubMed.18367972.s34.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s34.e0" e2="DDI-PubMed.18367972.s34.e1" /></sentence><sentence text="3 (0" /><sentence text="0-32" /><sentence text="5) ng*h/mL" /><sentence text=" Of the total metabolite AUC, 77" /><sentence text="5% was due to hydroxylated metabolites, while 39-O-desmethyl Sir (the main metabolite in adults) comprised only 8"><entity charOffset="46-64" id="DDI-PubMed.18367972.s39.e0" text="39-O-desmethyl Sir" /><entity charOffset="61-78" id="DDI-PubMed.18367972.s39.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s39.e0" e2="DDI-PubMed.18367972.s39.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s39.e0" e2="DDI-PubMed.18367972.s39.e1" /></sentence><sentence text="4% of the metabolites" /><sentence text=" This is clinically relevant, as 39-O-desmethyl Sir shows 86% to 127% cross-reactivity with the Sir immunoassay"><entity charOffset="33-47" id="DDI-PubMed.18367972.s41.e0" text="39-O-desmethyl" /><entity charOffset="48-61" id="DDI-PubMed.18367972.s41.e1" text="Sir" /><entity charOffset="96-109" id="DDI-PubMed.18367972.s41.e2" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s41.e0" e2="DDI-PubMed.18367972.s41.e0" /><pair ddi="false" e1="DDI-PubMed.18367972.s41.e0" e2="DDI-PubMed.18367972.s41.e1" /><pair ddi="false" e1="DDI-PubMed.18367972.s41.e0" e2="DDI-PubMed.18367972.s41.e2" /><pair ddi="false" e1="DDI-PubMed.18367972.s41.e1" e2="DDI-PubMed.18367972.s41.e1" /><pair ddi="false" e1="DDI-PubMed.18367972.s41.e1" e2="DDI-PubMed.18367972.s41.e2" /></sentence><sentence text=" Metabolites reached a median AUC of 60% of that of Sir, but the range was 2"><entity charOffset="52-54" id="DDI-PubMed.18367972.s42.e0" text="Sir" /></sentence><sentence text="6% to 136%" /><sentence text=" The age dependency of Sir metabolite formation was confirmed in a human liver microsome model"><entity charOffset="23-25" id="DDI-PubMed.18367972.s44.e0" text="Sir" /></sentence><sentence text=" On the basis of the age dependency of piperidine-hydroxy Sir, the authors postulate that the ontogeny of the drug disposition can be largely explained by developmental changes of the CYP2C8 expression"><entity charOffset="58-60" id="DDI-PubMed.18367972.s45.e0" text="Sir" /></sentence><sentence text=" In conclusion, both Sir and MMF drug disposition vary in children and adolescents from adult patients, most likely because of developmental changes of biliary transporters and metabolic enzymes"><entity charOffset="29-31" id="DDI-PubMed.18367972.s46.e0" text="MMF" /><entity charOffset="21-23" id="DDI-PubMed.18367972.s46.e1" text="Sir" /><pair ddi="false" e1="DDI-PubMed.18367972.s46.e1" e2="DDI-PubMed.18367972.s46.e1" /><pair ddi="false" e1="DDI-PubMed.18367972.s46.e1" e2="DDI-PubMed.18367972.s46.e0" /></sentence><sentence text="" /></document>